| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013331 For therapy of pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma |
| 01/31/2002 | US20020013328 For therapy of cancer or other proliferative diseases |
| 01/31/2002 | US20020013322 Novel compounds for enhancing chemotherapy |
| 01/31/2002 | US20020013319 For therapy of tumor or restenosis |
| 01/31/2002 | US20020013309 Pharmaceutical compositions and methods for use |
| 01/31/2002 | US20020013308 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier |
| 01/31/2002 | US20020013304 As needed rather than involving chronic pharmacotherapy; formulations and kits |
| 01/31/2002 | US20020013301 In an oral dosage form, providing a combination product analgesically effective when administered orally, but which is aversive in addicts at the same dose or higher dose than prescribed; prevention of drug abuse, drug dependency |
| 01/31/2002 | US20020013299 For enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent, which causes cytotoxic lesions at the O6-position of guanine; O6-alkylguanine-DNA alkyltransferase (AGT) inactivator |
| 01/31/2002 | US20020013297 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/31/2002 | US20020013286 Administering the adenoviral gene transfer vector (exogenous) encoding a gene product to a muscle and the vector is neutralized outside of the muscle by systemic neutralizing antibodies; using a chimeric coat protein for cell entry |
| 01/31/2002 | US20020013279 Hematopoietic stimulation |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013273 Method for producing sustained-release formulations |
| 01/31/2002 | US20020013268 Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012998 Gene transfer composition; for use in the transfection of mammalian cells |
| 01/31/2002 | US20020012992 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 01/31/2002 | US20020012965 Nucleotide sequences coding prfeerential polypeptides for use in the diagnosis and treatment of brain disorders and injury |
| 01/31/2002 | US20020012914 Transfection of preferential nucleotide sequences into aggregations; mix sample and nucleotide sequences, incubate, expose to electric pulse, recover transformed aggregations |
| 01/31/2002 | US20020012715 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera |
| 01/31/2002 | US20020012708 For preparation of medicaments for treatment of organ and tissue damages caused by radiation, infections, and chemically, especially of O-MALT system of small intestine, bone marrow, spleen, lymph nodes, liver |
| 01/31/2002 | US20020012700 Portion of pseudoephedrine is contained in core whereby release into environment of use is sustained, cetirizine is contained as immediate-release component; antiallergens, spasmolytics |
| 01/31/2002 | US20020012664 Combining agent to be tested, antibody or antigen-binding fragment which binds to amino terminal domain of mammalian CC-chemokine receptor 2, mammalian CC-chemokine receptor 2 or ligand-binding variant, measuring binding |
| 01/31/2002 | US20020012663 Inhibiting the growth of refractory tumors that are stimulated by a ligand of epidermal growth factor receptor (EGFR) in human patients, comprising treating the human patients with an effective amount of an EGFR/HER1 antagonist |
| 01/31/2002 | US20020012661 Methods for introducing genes into mammalian subjects |
| 01/31/2002 | US20020012641 Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 01/31/2002 | US20020012637 Administering to the oral cavity of a human or animal one or more lactic bacteria that are not part of resident microflora of mouth, that are low acidifying, and that are capable of adhering directly to pellicle of teeth |
| 01/31/2002 | DE19881732C1 New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases |
| 01/31/2002 | DE10035352A1 Verfahren zur Behandlung von instabiler Angina pectoris A method for the treatment of unstable angina |
| 01/31/2002 | DE10035144A1 Cyclische Aminosäurederivate Cyclic amino acid derivatives |
| 01/31/2002 | DE10033855A1 Transdermal therapeutic system for long-term treatment of hypertension, containing dicarboxylic acid angiotensin converting enzyme inhibitor converted into salt or ester derivative to improve stability |
| 01/31/2002 | DE10031179A1 Introducing active molecules into the nucleus of eukaryotic cells, useful for transfection and gene therapy, by applying controlled electrical pulse |
| 01/31/2002 | CA2797652A1 Multi-component biological transport systems |
| 01/31/2002 | CA2418282A1 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/31/2002 | CA2418204A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2418199A1 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2418194A1 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors |
| 01/31/2002 | CA2417134A1 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2416751A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416657A1 Fh-binding protein of streptococcus pneumoniae |
| 01/31/2002 | CA2416643A1 Ghrelin antagonists |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2416538A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/31/2002 | CA2416537A1 Calcilytic compounds |
| 01/31/2002 | CA2416414A1 Human kinases |
| 01/31/2002 | CA2416404A1 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 01/31/2002 | CA2416358A1 Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type i interferons |
| 01/31/2002 | CA2415900A1 Uses for nad synthetase inhibitors |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415606A1 Capsaicin receptor ligands |
| 01/31/2002 | CA2415585A1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415046A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2412392A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 01/31/2002 | CA2412373A1 Method for enhancing bone mineral density gain |
| 01/31/2002 | CA2411195A1 Aryl sulfonamides as serotonin antagonist for the treatment of obesity |
| 01/31/2002 | CA2411192A1 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation |
| 01/31/2002 | CA2410766A1 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2410682A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2410562A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | CA2354331A1 Composition and method for treatment of gastrointestinal disorders, hyperlipidemia, autoimmune diseases and obesity |
| 01/31/2002 | CA2354236A1 Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| 01/30/2002 | EP1176208A1 Koji molds and use thereof for preparing cholesterol-lowering products |
| 01/30/2002 | EP1176148A1 Benzothiadiazine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 01/30/2002 | EP1176146A1 Carbamoyl tetrahydropyridine derivatives |
| 01/30/2002 | EP1176145A1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 01/30/2002 | EP1176144A1 N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists |
| 01/30/2002 | EP1176141A1 HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR |
| 01/30/2002 | EP1176140A1 Amide compounds and medicinal use thereof |
| 01/30/2002 | EP1175911A2 Uses of recombinant colony stimulating factor-1 for treatment of leukopenia |
| 01/30/2002 | EP1175909A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/30/2002 | EP1175908A1 Oleoresin of hypericum perforatum l., method for obtaining said oleoresin and the use thereof |
| 01/30/2002 | EP1175907A1 Remedies |
| 01/30/2002 | EP1175905A1 Nutritional Composition |
| 01/30/2002 | EP1175902A1 Use of CS-866 (olmesartan) in the manufacture of a medicament for treating arteriosclerosis |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175888A2 Topical compositions comprising glycosylated hydroxystilbenes and their uses |
| 01/30/2002 | EP1175616A1 Methods for the diagnosis and treatment of metastatic prostate tumors |
| 01/30/2002 | EP1175508A1 Optical probes and assays |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175444A1 Amino-terminal modified parathyroid hormone (pth) analogs |
| 01/30/2002 | EP1175440A1 48 human secreted proteins |
| 01/30/2002 | EP1175439A1 49 human secreted proteins |
| 01/30/2002 | EP1175438A1 62 human secreted proteins |
| 01/30/2002 | EP1175434A2 Eplerenone crystalline form |
| 01/30/2002 | EP1175432A1 Processes for the synthesis of oligomers using phusphoramidite compositions |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175411A1 Cyclothiocarbamate derivatives as progesterone receptor modulators |
| 01/30/2002 | EP1175409A1 Pyrimidinones derivatives for the treatment of atherosclerosis |
| 01/30/2002 | EP1175408A1 Pyrimidinone compounds |
| 01/30/2002 | EP1175406A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands |
| 01/30/2002 | EP1175405A1 LACTAM INHIBITORS OF FXa AND METHOD |
| 01/30/2002 | EP1175404A1 Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| 01/30/2002 | EP1175401A1 Piperazine derivatives useful as ccr5 antagonists |